CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Paion AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Paion AG
Heussstrasse 25
Phone: +49 24144530p:+49 24144530 AACHEN, 52078  Germany Ticker: PA8PA8
Filed for Insolvency on 10/27/2023
On 10/27/2023, PAION AG and its subsidiary, PAION Deutschland GmbH, filed for the opening of Insolvency Proceedings with the Local Insolvency Court of Aachen. Attorney Dr. Mark Boddenberg was appointed as the preliminary Insolvency Administrator of PAION AG and PAION Deutschland GmbH.
Business Summary
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board MichaelSchlenk 5/25/2022 5/25/2022
Chairman of the Management Board, Chief Executive Officer GregorSiebert 12/1/2022 5/25/2022
Vice Chairwoman of the Supervisory Board Karin L.Dorrepaal 63 10/29/2012 10/29/2012
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
PAION Deutschland GmbH Heussstrasse 25 Aachen DE
CeNeS Pharmaceuticals plc Compass House Histon ENG UK

Business Names
Business Name
PA8
Paion AG
Paion Deutschland GmbH

General Information
Number of Employees: 64 (As of 6/30/2023)
Outstanding Shares: 7,133,699 (As of 10/24/2023)
Stock Exchange: FRA
Fax Number: +49 2414453100


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024